We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
11 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Amvuttra (vutrisiran) has been approved for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with polyneuropathy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OXLUMO lumasiran (as sodium) 94.5 mg/0.5 mL injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMVUTTRA, vutrisiran (as sodium) 25 mg / 0.5 mL solution for injection pre-filled syringe.
-
Prescription medicine decision summaryAmvuttra (vutrisiran) was approved for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
-
Australian Public Assessment Report (AusPAR)Givlaari (givosiran sodium) has been approved for the treatment of acute hepatic porphyria.
-
Prescription medicine registrationActive ingredients: lumasiran sodium.
-
Prescription medicine registrationActive ingredients: vutrisiran sodium.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GIVLAARI givosiran 189 mg/1mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONPATTRO patisiran 10 mg/5 mL concentrated injection for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KIMMTRAK tebentafusp 0.1 mg/0.5 mL concentrated solution for infusion vial.